Mihaela Mates

First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

Neal Ready, Matthew D. Hellmann, Mark M. Awad et al. · Journal of Clinical Oncology · 2019 · 596 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.

Vanessa Bernstein, Susan Ellard, Susan Dent et al. · Breast Cancer Research and Treatment · 2017 · 101 citations

Medicine, Oncology, Pharmacology +14

Hepatitis B and C virus infection in Romanian non‐Hodgkin's lymphoma patients

Andrei Cucuianu, Mariana Paţiu, Milena Duma et al. · British Journal of Haematology · 1999 · 75 citations

Medicine, Hematology, Oncology +11

A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer

Mark Clemons, Michael Ong, Carol Stober et al. · European Journal of Cancer · 2020 · 69 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy

Penelope A. Bradbury, Donald G. Morris, Garth Nicholas et al. · Lung Cancer · 2018 · 56 citations

Medicine, Oncology, Pharmacotherapy +10